GLUE
Monte Rosa Therapeutics Inc
11.70$
-1.4%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +20.5% | -12.2% | +29.0% | -8.4% | +39.2% | -10.4% | -8.5% | +27.9% | -2.4% | +64.1% | -5.5% | |
| – | +29.1% | -15.7% | +39.6% | -9.6% | +50.3% | -12.0% | -9.9% | +34.2% | -2.1% | +72.3% | -6.1% | |
| – | +116.9% | -22.1% | +9.1% | +15.4% | +78.6% | -65.0% | -11.6% | +200.1% | -37.7% | +23.1% | -43.6% | |
| – | +30.2% | -17.0% | +35.9% | -7.6% | +53.7% | -12.4% | -10.9% | +34.6% | -3.6% | +76.7% | -6.8% | |
| – | +71.8% | +19.0% | +1,537.6% | -94.0% | -70.9% | +713.9% | +68.3% | +109.5% | -7.4% | +0.2% | +113.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +84.2% | -8.3% | +4.6% | -8.2% | +96.9% | -45.3% | -22.5% | +133.9% | +0.7% | -0.5% | -1.6% | |
| – | +106.1% | -11.4% | +2.6% | -1.7% | +276.9% | -62.3% | -29.3% | +46.8% | +4.5% | +10.6% | -5.9% | |
| – | +9.8% | +5.8% | +3.8% | +5.0% | +1.9% | +4.1% | +5.9% | +3.6% | +3.7% | +2.0% | +3.3% | |
| – | +102.8% | -38.8% | -5.2% | -38.5% | +332.8% | -62.3% | -14.0% | +160.0% | -75.5% | +122.5% | -9.5% | |
| – | -2.9% | -14.9% | +47.3% | -8.6% | +8.5% | +23.4% | -2.6% | -8.3% | -5.2% | +123.9% | -6.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +14.3% | +5.7% | +18.4% | +15.1% | -25.1% | +35.0% | -25.6% | +0.1% | +6.1% | +28.6% | +1.1% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.